Anonymous (2026). Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials.. European heart journal.
Anonymous. Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials.. European heart journal. 2026; PMID: 42183881
Anonymous. Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials.[J]. European heart journal. 2026.
@article{paper2026,
author = {Anonymous},
title = {Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials.},
journal = {European heart journal},
year = {2026},
note = {PMID: 42183881},
}
TY - JOUR AU - Anonymous TI - Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. T2 - European heart journal PY - 2026 AN - PMID:42183881 ER -
There is interest in developing lipoprotein(a) [Lp(a)] lowering therapies. Cholesteryl ester transfer protein inhibitors lower Lp(a), however the effects of the selective inhibitor obicetrapib on Lp(a) levels in high cardiovascular risk patients have not been fully elucidated. This analysis investigated the effect of obicetrapib on Lp(a).